Madhuchandra Kenchegowda

Dr. Madhuchandra Kenchegowda

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MKMadhuchandra Kenchegowda
Madhuchandra Kenchegowda
MRMohamed Rahamathulla
Mohamed Rahamathulla
UHUmme Hani
Umme Hani
MBM.Yasmin Begum
M.Yasmin Begum
SGSagar Guruswamy
Sagar Guruswamy
DGDevegowda Vishkante Gowda
Devegowda Vishkante Gowda
Cancer is a group of disorders characterized by uncontrolled cell growth that affects around 11 million people each year globally. Nanocarrier-based systems are extensively used in cancer imaging, diagnostics as well as therapeutics; owing to their promising features and potential to augment therapeutic efficacy. The focal point of research remains to develop new-fangled smart nanocarriers that can selectively respond to cancer-specific conditions and deliver medications to target cells efficiently. Nanocarriers deliver loaded therapeutic cargos to the tumour site either in a passive or active mode, with the least drug elimination from the drug delivery systems. This review chiefly focuses on current advances allied to smart nanocarriers such as dendrimers, liposomes, mesoporous silica nanoparticles, quantum dots, micelles, superparamagnetic iron-oxide nanoparticles, gold nanoparticles and carbon nanotubes, to list a few. Exhaustive discussion on crucial topics like drug targeting, surface decorated smart-nanocarriers and stimuli-responsive cancer nanotherapeutics responding to temperature, enzyme, pH and redox stimuli have been covered.

17 April 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
MKMadhuchandra Kenchegowda
Madhuchandra Kenchegowda
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
UHUmme Hani
Umme Hani
Adel Al FateaseAdel Al Fatease
Adel Al Fatease
FFfarhat fatima
farhat fatima
HKHeena Shijauddin Kazi
Heena Shijauddin Kazi

18 February 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RARavi Kiran Ammu
Ravi Kiran Ammu
KGKusuma Kumari Garikapati
Kusuma Kumari Garikapati
PKPraveen T. Krishnamurthy
Praveen T. Krishnamurthy
AJASHA P JOHNSON
ASHA P JOHNSON
MKMadhuchandra Kenchegowda
Madhuchandra Kenchegowda
Syed Mohd Danish RizviSyed Mohd Danish Rizvi
Syed Mohd Danish Rizvi
Pediatric brain tumors are the major cause of pediatric cancer mortality. They comprise a diverse group of tumors with different developmental origins, genetic profiles, therapeutic options, and outcomes. Despite many technological advancements, the treatment of pediatric brain cancers has remained a challenge. Treatment options for pediatric brain cancers have been ineffective due to non-specificity, inability to cross the blood–brain barrier, and causing off-target side effects. In recent years, nanotechnological advancements in the medical field have proven to be effective in curing challenging cancers like brain tumors. Moreover, nanoparticles have emerged successfully, particularly in carrying larger payloads, as well as their stability, safety, and efficacy monitoring. In the present review, we will emphasize pediatric brain cancers, barriers to treating these cancers, and novel treatment options.